ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Gynecologic Cancers

Gynecologic Cancers

The use of cediranib as concurrent treatment with chemotherapy and as maintenance therapy in relapsed ovarian cancer was not associated with declines in quality of life.

The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

A novel compound known as PM01183 showed promising activity in a two-stage phase II trial of women with platinum-resistant/refractory ovarian cancer.

Thromboprophylaxis with oral apixaban was similar to subcutaneous enoxaparin with regard to safety outcomes in women undergoing surgery for suspected gynecologic malignancies.

In this review we discuss preoperative diagnosis and the role of pathology, and we summarize the current literature regarding the management of uterine sarcomas.

The addition of the immune therapy motolimod to pegylated liposomal doxorubicin failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial.

Pages

Subscribe to Gynecologic Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.